Last reviewed · How we verify

Caerulein (CERULETIDE)

FDA-approved approved Recombinant protein Quality 17/100

Ceruletide is a marketed diagnostic aid that stimulates digestive processes by mimicking the natural hormone cholecystokinin through binding to the cholecystokinin receptor type A. Its key competitive advantage lies in its specific mechanism of action and the protection of its key composition patent until 2028. The primary risk is the presence of off-patent competitors such as magnesium sulfate, which may limit market exclusivity and pricing power.

At a glance

Generic nameCERULETIDE
Drug classceruletide
TargetCholecystokinin receptor type A
ModalityRecombinant protein
Therapeutic areaGastroenterology
PhaseFDA-approved
First approval1982

Approved indications

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions